https://www.selleckchem.com/products/cc-99677.html
Prostate cancer (PCa) is the commonest non-cutaneous malignancy worldwide and the second cause of cancer death among males in the USA. Approval of the new androgen receptor axis-targeted (ARAT) agents (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) has altered the course of advanced PCa. We aimed to assess the endocrine and metabolic adverse events associated with treatment using ARAT compounds. We searched the PubMed, Cochrane Library, and Scopus databases from database inception to August 2020. We included randomiz
Like
Comment
Share
